A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Status:
Completed
Trial end date:
2019-01-02
Target enrollment:
Participant gender:
Summary
Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disease of the central
nervous system (CNS) that is regarded as the foremost cause of non-traumatic neurologic
disability in adults in North America. Spasticity is a common complication in MS and occurs
in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement
characterized by increased resistance to stretching, clonus, and exaggerated deep reflexes.
Osmotica Pharmaceutical is currently developing arbaclofen extended-release tablets (AERT)
for the treatment of spasticity in patients with MS.